RT @TitiValk: https://t.co/MltVHYdnLS décembre 2023 #NASH Recently, a phase 2 placebo-controlled study, the DESTINY-1, evaluated increasing…
62 followers
3,698 followers
https://t.co/MltVHYdnLS décembre 2023 #NASH Recently, a phase 2 placebo-controlled study, the DESTINY-1, evaluated increasing doses of PXL065 in 117 patients with fibrotic (F1 to F3) MASH. It showed promising results #POXEL 👉 PXL065!
3,039 followers
New Research: MASLD treatment—a shift in the paradigm is imminent: MASLD prevalence is growing towards the leading cause of end-stage liver disease. Up to today, the most effective treatment is weight loss. Weight loss… https://t.co/34a7hxM77h #medicalcare